News

International Headache Week (IHW), set to take place March 15-21, 2026, is a global initiative led by Lifting The Burden (LTB) to raise awareness of the burden of headache disorders worldwide.

Apply to the 2026 Headache Assistant Editor Leadership Opportunity Program to receive training and expand the impact of the Headache Journal and AHS. 

The leadership team at Headache is excited to announce that Headache journal will transition to online-only publication beginning in January 2026.

The American Headache Society is offering three upcoming research grants to support investigators at all career stages. Opportunities include the Innovative Project Award, Investigator-Initiated Research Awards, and the Headache & Migraine Competitive Grant Program. 

The Alliance for Headache Disorders Advocacy (AHDA) is thrilled to announce that the Headache Education, Access, Diagnosis, and Care Health Equity Act (HEADACHE Act, H.R. 5536) has been introduced in the House of Representatives by Representatives Trahan and Fitzpatrick. This bipartisan legislation is a historic first for our community; the first standalone bill focused on migraine and headache disorders.

The American Headache Society is proud to share highlights from the 2025 Headache Medicine Fellowship Match. This year saw record program participation, strong applicant success, and continued growth in the field. Explore the full recap, including match statistics, fellowship resources, and opportunities for future applicants.

Axsome Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has approved AXS-07 (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. This novel oral medication combines meloxicam, a nonsteroidal anti-inflammatory drug, and rizatriptan, a serotonin receptor agonist, to provide rapid and sustained relief from migraine pain.

In a groundbreaking initiative, a multi-stakeholder international group of experts led by the American Headache Society in close collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) and the International Headache Society (IHS), has identified critical research priorities for the headache field. 

Adult neurology residents, pediatric neurology residents, postdoctoral researchers, and headache medicine fellows are eligible to apply for a 2-year term, beginning July 1, 2024 and ending June 30, 2026.

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.

Headache: The Journal of Head and Face Pain is recruiting a new class of trainees to join its Editorial Board through the Assistant Editor Team Program.

Headache® has begun to resume the quarterly online release of its virtual issues. Virtual issues can be found at headachejournal.org and represent a carefully curated list of recent publications from the journal

Learn about the diagnosis, symptoms and treatment of migraine specifically for your adolescent patients.